longevity sector
立場別 · 2 論調 本号全体
Longevity.Technology · United Kingdom · NewLimit raises $435M to take cell-reprogramming into humans
Sets the round in 2026's longevity surge, ~$3.74B raised across 49 financings in Q1 alone, on track for an $8–9B full year, and treats epigenetic reprogramming as the thesis pulling pharma money (Lilly) into aging biology.
“Longevity biotech investment 2026: we're set for a breakout year.”
Longevity.Technology · United Kingdom · Retro Biosciences raises at $1.8B as Alzheimer's trial advances
Treats the markdown as a reality check on 2025's longevity froth while crediting the advancing Alzheimer's program; notes Retro's mix of in-vivo gene therapies, cell-replacement and aggregate-clearance approaches in its bid to add 10 healthy years to lifespan.
“Retro Bio's $1.8b moment: Hopes up as Alzheimer's trial advances.”